These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12482605)

  • 1. A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity.
    Schmidt JJ; Stafford RG
    FEBS Lett; 2002 Dec; 532(3):423-6. PubMed ID: 12482605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compounds.
    Minnow YV; Goldberg R; Tummalapalli SR; Rotella DP; Goodey NM
    Arch Biochem Biophys; 2017 Mar; 618():15-22. PubMed ID: 28137423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease.
    Sukonpan C; Oost T; Goodnough M; Tepp W; Johnson EA; Rich DH
    J Pept Res; 2004 Feb; 63(2):181-93. PubMed ID: 15009541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.
    Zuniga JE; Hammill JT; Drory O; Nuss JE; Burnett JC; Gussio R; Wipf P; Bavari S; Brunger AT
    PLoS One; 2010 Jun; 5(6):e11378. PubMed ID: 20614028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition.
    Lai H; Feng M; Roxas-Duncan V; Dakshanamurthy S; Smith LA; Yang DC
    Arch Biochem Biophys; 2009 Nov; 491(1-2):75-84. PubMed ID: 19772855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope targeting of tertiary protein structure enables target-guided synthesis of a potent in-cell inhibitor of botulinum neurotoxin.
    Farrow B; Wong M; Malette J; Lai B; Deyle KM; Das S; Nag A; Agnew HD; Heath JR
    Angew Chem Int Ed Engl; 2015 Jun; 54(24):7114-9. PubMed ID: 25925721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buforin I, a natural peptide, inhibits botulinum neurotoxin B activity in vitro.
    Garcia GE; Moorad DR; Gordon RK
    J Appl Toxicol; 1999 Dec; 19 Suppl 1():S19-22. PubMed ID: 10594894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography.
    Kumaran D; Adler M; Levit M; Krebs M; Sweeney R; Swaminathan S
    Bioorg Med Chem; 2015 Nov; 23(22):7264-73. PubMed ID: 26522088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzoquinones as inhibitors of botulinum neurotoxin serotype A.
    Bremer PT; Hixon MS; Janda KD
    Bioorg Med Chem; 2014 Aug; 22(15):3971-81. PubMed ID: 24984937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling.
    Kumar G; Kumaran D; Ahmed SA; Swaminathan S
    Acta Crystallogr D Biol Crystallogr; 2012 May; 68(Pt 5):511-20. PubMed ID: 22525749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite.
    Schmidt JJ; Stafford RG; Bostian KA
    FEBS Lett; 1998 Sep; 435(1):61-4. PubMed ID: 9755859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
    Schmidt JJ; Stafford RG
    Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hinge peptide combinatorial libraries for inhilbitors of botulinum neurotoxins and saxitoxin: deconvolution strategy.
    Moore GJ; Moore DM; Roy SS; Hayden LJ; Hamilton MG; Chan NW; Lee WE
    Mol Divers; 2006 Feb; 10(1):9-16. PubMed ID: 16404524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate.
    Zuniga JE; Schmidt JJ; Fenn T; Burnett JC; Araç D; Gussio R; Stafford RG; Badie SS; Bavari S; Brunger AT
    Structure; 2008 Oct; 16(10):1588-97. PubMed ID: 18940613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate binding mode and its implication on drug design for botulinum neurotoxin A.
    Kumaran D; Rawat R; Ahmed SA; Swaminathan S
    PLoS Pathog; 2008 Sep; 4(9):e1000165. PubMed ID: 18818739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E.
    Agarwal R; Swaminathan S
    J Biol Chem; 2008 Sep; 283(38):25944-51. PubMed ID: 18658150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F.
    Schmidt JJ; Stafford RG
    Appl Environ Microbiol; 2003 Jan; 69(1):297-303. PubMed ID: 12514008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing BoNT/A protease exosites: implications for inhibitor design and light chain longevity.
    Xue S; Javor S; Hixon MS; Janda KD
    Biochemistry; 2014 Nov; 53(43):6820-4. PubMed ID: 25295706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.
    Li B; Cardinale SC; Butler MM; Pai R; Nuss JE; Peet NP; Bavari S; Bowlin TL
    Bioorg Med Chem; 2011 Dec; 19(24):7338-48. PubMed ID: 22082667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.
    Mizanur RM; Frasca V; Swaminathan S; Bavari S; Webb R; Smith LA; Ahmed SA
    J Biol Chem; 2013 Aug; 288(33):24223-33. PubMed ID: 23779108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.